ONCS - ONCS STOCK NEWS

OncoSec Medical announced a collaboration with Merck to conduct a global Phase 3 clinical trial, KEYNOTE-C87, evaluating the combination of OncoSec's TAVO™ and Merck's KEYTRUDA® in metastatic melanoma patients resistant to prior treatments. The trial aims to support potential FDA accelerated approval. Approximately 400 patients will be enrolled across the U.S., Canada, EU, and Australia. TAVO™ has received Fast Track designation and is recognized as a potentially first-in-class therapy.

OncoSec Medical Incorporated (NASDAQ:ONCS) announced the resignation of CEO Daniel O'Connor, effective June 25, 2021. Brian Leuthner, previously the Chief Operating Officer, has been appointed as Interim CEO. O'Connor's tenure saw significant advancements, including the pivotal KEYNOTE-695 study in metastatic melanoma. Leuthner, with over 32 years in biotech, aims to build on O'Connor's momentum and enhance the firm's clinical programs. The company focuses on TAVO™, its leading gene therapy technology, which has shown promise in treating various cancers.

OncoSec Medical Incorporated (NASDAQ:ONCS) appointed Jeffrey Silverman as Vice President of Product Engineering on June 14, 2021. With over 20 years of experience in medical device development and manufacturing, Silverman previously served at Ichor Medical Systems, overseeing electroporation technologies crucial for cancer therapy. He replaces John Rodriguez, who retired after five years. Silverman's expertise aligns with OncoSec's mission to advance its lead candidate, TAVO™, which has shown promise in clinical trials for metastatic melanoma and triple-negative breast cancer.

OncoSec Medical Incorporated (NASDAQ:ONCS) will present an overview at the Raymond James Human Health Innovation Conference from June 21 to June 23, 2021. The presentation is scheduled for 12:00pm ET on June 21. For those unable to attend, a replay will be available on OncoSec's website for 90 days. OncoSec focuses on developing cytokine-based immunotherapies, particularly TAVO™, aimed at enhancing the immune response against cancer. The company continues to explore new therapeutic candidates for various cancer types.

OncoSec Medical (NASDAQ:ONCS) appointed Dr. Robert M. Schinagl as Vice President of Program and Alliance Management on May 17, 2021. With over 20 years in biotech, Dr. Schinagl aims to strengthen partnerships and drive development of OncoSec's lead product, TAVO™, an immunotherapy for cancer. His previous roles include COO at Prothex Pharma, where he managed strategic operations and collaborations. Dr. Schinagl will receive 35,000 stock options, vesting over two years. TAVO™ has demonstrated promising results in clinical trials and has received Orphan Drug and Fast-Track Designation from the FDA.

OncoSec Medical (NASDAQ: ONCS) announced it will present encore interim data from its KEYNOTE-695 Phase 2b trial for TAVO™ (tavokinogene telseplasmid) in combination with KEYTRUDA® at the 10th World Congress of Melanoma. The trial targets anti-PD-1 resistant metastatic melanoma patients. Results indicate a 30% overall response rate with no serious adverse events, suggesting significant therapeutic potential. TAVO has received Fast Track Designation from the FDA for use in metastatic melanoma, enhancing its clinical development prospects.

OncoSec Medical has received CE mark certification for its GenPulse™ gene delivery device, essential for its commercialization in Europe. This certification confirms that GenPulse meets performance, quality, and safety standards, allowing marketing in the European Economic Area and Switzerland. The device enhances anti-cancer agent uptake in tumor cells through electroporation. This milestone follows ISO 13485 certification for OncoSec's quality management system, further validating the company’s capabilities in developing innovative cancer treatments.

OncoSec Medical (NASDAQ:ONCS) will sponsor a webinar on March 31, 2021, focusing on anti-PD-1 checkpoint refractory metastatic melanoma, featuring leading oncologists discussing the ILLUMINATE-301 trial results. KOLs include Gregory Daniels, Paolo Ascierto, John M. Kirkwood, and Matteo Carlino, who will cover various aspects of immunotherapy. This event aims to provide insights into the commercial outlook for melanoma treatments. OncoSec's investigational product candidate, TAVO™, is at the forefront of developing cytokine-based immunotherapies targeting cancer.

OncoSec Medical (NASDAQ: ONCS) announced the publication of research in Clinical Cancer Research demonstrating its lead candidate TAVO™, a DNA-based interleukin-12 therapy, can activate tumor-specific antitumor immunity in triple-negative breast cancer (TNBC) patients. Key findings indicated that TAVO treatment enhanced CXCR3 gene signature and CD8+ T cell infiltration, potentially improving response to anti-PD-1 therapy. The study suggests TAVO's significant role in addressing treatment resistance in TNBC, highlighting its potential to stimulate the immune response and combine effectively with existing therapies.